Antibiotic resistance is emerging as a silent yet deadly crisis in Australia, with drug-resistant infections claiming more lives annually than road accidents. According to experts, resistant infections cause an estimated 1,600 deaths each year, surpassing the country’s road toll of 1,300 fatalities. Despite the gravity of the situation, public awareness and policy action remain alarmingly insufficient.
The issue of antibiotic resistance is twofold: bacteria are evolving to resist existing antibiotics, and the development of new antibiotics is not keeping pace. The rise of “superbugs”—bacteria resistant to multiple antibiotics—poses a significant threat to modern medicine, complicating treatments for surgeries, cancer therapies, and even minor injuries.
The Growing Threat of Superbugs
Antibiotic resistance is exacerbated by the overuse and misuse of antibiotics. Globally, about two-thirds of antibiotics are administered to animals, often to promote growth rather than treat illness. Although Australia maintains relatively low agricultural antibiotic use, it ranks high in human antibiotic prescriptions, with many deemed unnecessary.
Part of the problem lies in the lack of rapid diagnostic tools to distinguish between bacterial and viral infections, leading to precautionary antibiotic prescriptions. Unlike other drug classes, antibiotics are often perceived as safe, yet they can cause significant side effects, including damage to hearing, muscles, and kidneys.
The Economic Hurdle in Antibiotic Development
The pharmaceutical industry faces economic challenges in developing new antibiotics. Most major companies have abandoned early-stage antibiotic research due to low profitability. Unlike blockbuster drugs, new antibiotics must be reserved for critical cases, limiting their market potential. Consequently, venture capital has largely withdrawn from the sector, leaving a sparse development pipeline.
“A life-saving antibiotic might earn $15,000 per course, while cancer therapies can charge $500,000 for a therapy that may or may not work.”
This economic disparity has led to the bankruptcy of several antibiotic-focused biotech companies, further stalling innovation. Currently, only 50 to 60 antibiotics are in human trials, compared to thousands of cancer drugs at the same stage.
Access and Policy Challenges
Access to new antibiotics is another significant issue. Lower-income countries with high resistance rates often cannot afford them, while in Australia, the cost of registering new antibiotics often exceeds potential sales. Of the 23 antibiotics approved globally since 2013, only two are available in Australia, forcing doctors to apply for special access frequently.
Australia’s fragmented approach to managing antibiotics and antimicrobial resistance hinders effective action. The Australian Antimicrobial Resistance Network (AAMRNet) aims to unify efforts across various sectors, but its funding remains precarious. Participation in global initiatives like CARB-X and GARDP could bolster antibiotic discovery efforts, yet Australia has not contributed financially to these programs.
Solutions and Future Directions
To address these challenges, Australia must invest in research and infrastructure. A proposed solution is adopting a “Netflix” subscription model for antibiotic reimbursement, ensuring access regardless of usage. Public advocacy and increased funding for research are crucial, as grant success rates have plummeted, and significant funds remain unspent.
“Look to the person on your left, then to the person on your right. One of you has taken an antibiotic in the past year. If it didn’t work, would that person still be alive?”
Supporting researchers and fostering innovation in antibiotic development are essential to combat this growing threat. As antibiotic resistance continues to rise, coordinated efforts at national and global levels are imperative to safeguard public health and preserve the effectiveness of these critical drugs.
Mark Blaskovich, a professor at the Institute for Molecular Bioscience, University of Queensland, emphasizes the need for immediate action to prevent further loss of life and ensure that antibiotics remain a cornerstone of modern medicine.
